All lobbying filings

EMERGENT STRATEGIES

EMERGENT STRATEGIES filed a Q3 report for GENBIOPRO, INC. on October 21, 2026.

Lobbying for GENBIOPRO, INC. · Generic Pharmaceutical Manufacturer

All filings by EMERGENT STRATEGIES · Everything GENBIOPRO, INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 21, 2026

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

Nevada

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Pharmacy

FDA Approval of generic mifepristone and relate Risk Evaluation Mitigation Strategies (REMS)

Veterans

VA rule making on providing abortion services to veterans

Health Issues

Issues related to medication abortion; Issues related to abortion access

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.